JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
There are no items in your shopping cart
Featured Products
Axon 2565
CAS [862974-25-2]
MF C17H14N4O3SMW 354.38
First-in-class small-molecule activator targeting E1 ligase mediated SERCA2a SUMOylation. N106 treatment increases contractile properties of cultured rat cardiomyocytes and significantly improves ventricular function in mice with heart failure.
KEYWORDS: N106 | supplier | E1 ligase activator | N-106 | CAS [862974-25-2] | Ubiquitin | Ubiquitin Ligase (E1) | Activator | small ubiquitin-like modifier type 1 | SUMO-1 | SERCA2a | SUMOylation | heart failure | cardiomyocyte | cardiac | sarcoplasmic reticulum | calcium | ATPase
N-(4-methoxybenzo[d]thiazol-2-yl)-5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-amine
[862974-25-2]
The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.
Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!
* Required Fields